116 related articles for article (PubMed ID: 24510538)
1. Gene therapy of lung adenocarcinoma using herpes virus expressing a fusogenic membrane glycoprotein.
Zhu B; Yang JR; Jiang YQ; Chen SF; Fu XP
Cell Biochem Biophys; 2014 Jul; 69(3):583-7. PubMed ID: 24510538
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor effects of gene therapy with GALV membrane fusion glycoprotein in lung adenocarcinoma.
Zhu B; Yang JR; Fu XP; Jiang YQ
Cell Biochem Biophys; 2014 Jul; 69(3):577-82. PubMed ID: 24519667
[TBL] [Abstract][Full Text] [Related]
3. [The construction of recombinant type I herpes simplex virus carrying GALV.fus gene and its antitumor effect in nude mice].
Zhu M; Yang JR; Jiang YQ; Chen SF; Fu XP; Tian ZD
Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Mar; 42(2):152-6. PubMed ID: 21500543
[TBL] [Abstract][Full Text] [Related]
4. Packaging, amplification, and appraisal of the recombinant tumor-selective type I herpes simplex virus carrying GALV.fus gene.
Bing Z; Jianru Y; Yuequan J; Shifeng C; Xinping F
Cell Biochem Biophys; 2014 Sep; 70(1):321-6. PubMed ID: 24687598
[TBL] [Abstract][Full Text] [Related]
5. Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect.
Fu X; Tao L; Jin A; Vile R; Brenner MK; Zhang X
Mol Ther; 2003 Jun; 7(6):748-54. PubMed ID: 12788648
[TBL] [Abstract][Full Text] [Related]
6. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
[TBL] [Abstract][Full Text] [Related]
7. Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas.
Galanis E; Bateman A; Johnson K; Diaz RM; James CD; Vile R; Russell SJ
Hum Gene Ther; 2001 May; 12(7):811-21. PubMed ID: 11339897
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy for malignant glioma using Sindbis vectors expressing a fusogenic membrane glycoprotein.
Zhang J; Frolov I; Russell SJ
J Gene Med; 2004 Oct; 6(10):1082-91. PubMed ID: 15368589
[TBL] [Abstract][Full Text] [Related]
9. Syncytia formation affects the yield and cytotoxicity of an adenovirus expressing a fusogenic glycoprotein at a late stage of replication.
Guedan S; Gros A; Cascallo M; Vile R; Mercade E; Alemany R
Gene Ther; 2008 Sep; 15(17):1240-5. PubMed ID: 18509378
[TBL] [Abstract][Full Text] [Related]
10. Gene therapy for acute myeloid leukemia using Sindbis vectors expressing a fusogenic membrane glycoprotein.
Tan L; Xu B; Liu R; Liu H; Tan H; Huang W
Cancer Biol Ther; 2010 Mar; 9(5):350-7. PubMed ID: 20061812
[TBL] [Abstract][Full Text] [Related]
11. Fusogenic membrane glycoproteins induce syncytia formation and death in vitro and in vivo: a potential therapy agent for lung cancer.
Lin EH; Salon C; Brambilla E; Lavillette D; Szecsi J; Cosset FL; Coll JL
Cancer Gene Ther; 2010 Apr; 17(4):256-65. PubMed ID: 19893593
[TBL] [Abstract][Full Text] [Related]
12. A hyperfusogenic gibbon ape leukemia envelope glycoprotein: targeting of a cytotoxic gene by ligand display.
Fielding AK; Chapel-Fernandes S; Chadwick MP; Bullough FJ; Cosset FL; Russell SJ
Hum Gene Ther; 2000 Apr; 11(6):817-26. PubMed ID: 10779159
[TBL] [Abstract][Full Text] [Related]
13. Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas.
Allen C; McDonald C; Giannini C; Peng KW; Rosales G; Russell SJ; Galanis E
J Gene Med; 2004 Nov; 6(11):1216-27. PubMed ID: 15459967
[TBL] [Abstract][Full Text] [Related]
14. Construction of a replication-competent retroviral vector for expression of the VSV-G envelope glycoprotein for cancer gene therapy.
Jin SY; Jung YT
Arch Virol; 2020 May; 165(5):1089-1097. PubMed ID: 32146506
[TBL] [Abstract][Full Text] [Related]
15. Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control.
Simpson GR; Han Z; Liu B; Wang Y; Campbell G; Coffin RS
Cancer Res; 2006 May; 66(9):4835-42. PubMed ID: 16651439
[TBL] [Abstract][Full Text] [Related]
16. [An experimental study on targeting suicide gene therapy for lung cancer with HSV-TK driven by hTERT promoter].
Wang YP; Tang XJ; Zhou QH; Che GW; Chen XH; Zhu DX
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):701-5. PubMed ID: 19024294
[TBL] [Abstract][Full Text] [Related]
17. Oncolysis using herpes simplex virus type 1 engineered to express cytosine deaminase and a fusogenic glycoprotein for head and neck squamous cell carcinoma.
Price DL; Lin SF; Han Z; Simpson G; Coffin RS; Wong J; Li S; Fong Y; Wong RJ
Arch Otolaryngol Head Neck Surg; 2010 Feb; 136(2):151-8. PubMed ID: 20157061
[TBL] [Abstract][Full Text] [Related]
18. Active adenoviral vascular penetration by targeted formation of heterocellular endothelial-epithelial syncytia.
Chen HH; Cawood R; El-Sherbini Y; Purdie L; Bazan-Peregrino M; Seymour LW; Carlisle RC
Mol Ther; 2011 Jan; 19(1):67-75. PubMed ID: 20877345
[TBL] [Abstract][Full Text] [Related]
19. Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease-substrate interaction.
Johnson KJ; Peng KW; Allen C; Russell SJ; Galanis E
Gene Ther; 2003 May; 10(9):725-32. PubMed ID: 12704411
[TBL] [Abstract][Full Text] [Related]
20. Highly efficient tumor transduction and antitumor efficacy in experimental human malignant mesothelioma using replicating gibbon ape leukemia virus.
Kubo S; Takagi-Kimura M; Logg CR; Kasahara N
Cancer Gene Ther; 2013 Dec; 20(12):671-7. PubMed ID: 24201868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
